{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:38:34Z","timestamp":1782779914838,"version":"3.54.5"},"reference-count":64,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,2,5]]},"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapies that specifically target the CD19 antigen have emerged as a highly effective treatment option in patients with refractory B-cell hematological malignancies. Safety and efficacy outcomes from the pivotal prospective clinical trials of axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel and the retrospective, postmarketing, real-world analyses have confirmed high response rates and durable remissions in patients who had failed multiple lines of therapy and had no meaningful treatment options. Although initially administered in the inpatient setting, there has been a growing interest in delivering CAR-T cell therapy in the outpatient setting; however, this has not been adopted as standard clinical practice for multiple reasons, including logistic and reimbursement issues. CAR-T cell therapy requires a multidisciplinary approach and coordination, particularly if given in an outpatient setting. The ability to monitor patients closely is necessary and proper protocols must be established to respond to clinical changes to ensure efficient, effective and rapid evaluation either in the clinic or emergency department for management decisions regarding fever, sepsis, cytokine release syndrome and neurological events, specifically immune effector cell-associated neurotoxicity syndrome. This review presents the authors\u2019 institutional experience with the preparation and delivery of outpatient CD19-directed CAR-T cell therapy.<\/jats:p>","DOI":"10.1136\/jitc-2020-002056","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T11:55:36Z","timestamp":1618228536000},"page":"e002056","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":85,"title":["Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02348216","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02445248","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02631044","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02435849","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03483103","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03744676","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"G Doug","family":"Myers","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology\/Cellular Therapy and Stem Cell Transplantation, Children's Mercy Hospital; University of Missouri Kansas City, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Verneris","sequence":"additional","affiliation":[{"name":"Cancer and Blood Disorders, Section of Blood and Marrow Transplantation and Cellular Therapy, University of Colorado, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T","family":"Maziarz","sequence":"additional","affiliation":[{"name":"BMT & Cell Therapy Program, Division of Hematology\/Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"2025100314192681000_9.4.e002056.1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"2025100314192681000_9.4.e002056.2","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-114152","article-title":"Axicabtagene ciloleucel (axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: real world experience","volume":"132","author":"Nastoupil","year":"2018","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.3","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129107","article-title":"Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients in the Juliet trial","volume":"134","author":"Westin","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.4","unstructured":"KYMRIAH [US prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2018."},{"key":"2025100314192681000_9.4.e002056.5","unstructured":"Yescarta (axicabtagene ciloleucel) . [US prescribing information]. Santa Monica, California: Kite Pharma, Inc, 2019."},{"key":"2025100314192681000_9.4.e002056.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"2025100314192681000_9.4.e002056.7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2025100314192681000_9.4.e002056.8","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-130983","article-title":"Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry","volume":"134","author":"Jaglowski","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.9","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1016\/j.clml.2019.07.190","article-title":"Real world experience of Tisagenlecleucel chimeric antigen receptor (CAR) T-cells targeting CD19 in patients with acute lymphoblastic leukemia (all) and diffuse large B-cell lymphoma (DLBCL) using the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry","volume":"19","author":"Pasquini","year":"2019","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"2025100314192681000_9.4.e002056.10","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124750","article-title":"Post-Marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, Axicabtagene Ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.11","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127490","article-title":"A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas","volume":"134","author":"Riedell","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.12","doi-asserted-by":"crossref","unstructured":"Riedell PA WC , Nastoupil LJ , Pennisi M , et al . A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas. Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR. Oral 52 2020.","DOI":"10.1016\/j.bbmt.2019.12.108"},{"key":"2025100314192681000_9.4.e002056.13","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100314192681000_9.4.e002056.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100314192681000_9.4.e002056.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2025100314192681000_9.4.e002056.17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"2025100314192681000_9.4.e002056.18","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"key":"2025100314192681000_9.4.e002056.19","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2025100314192681000_9.4.e002056.20","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"2025100314192681000_9.4.e002056.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100314192681000_9.4.e002056.22","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Schuster","year":"2020","journal-title":"Blood Adv"},{"key":"2025100314192681000_9.4.e002056.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004"},{"key":"2025100314192681000_9.4.e002056.24","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"key":"2025100314192681000_9.4.e002056.25","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/EDBK_238693","article-title":"Chimeric antigen receptor T-cell therapies for aggressive B-cell lymphomas: current and future state of the art","volume":"39","author":"Abramson","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100314192681000_9.4.e002056.26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"2025100314192681000_9.4.e002056.27","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123051","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.28","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.bbmt.2019.12.105","article-title":"Risk-adapted preemptive tocilizumab decreases severe cytokine release syndrome (CRS) after CTL019 CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (B-ALL)","volume":"26","author":"Myers","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100314192681000_9.4.e002056.29","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126081","article-title":"Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory large B cell lymphoma","volume":"134","author":"Topp","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.30","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.1016\/j.clml.2019.07.158","article-title":"Correlative analyses of cytokine release syndrome and neurological events in tisagenlecleucel-treated relapsed\/refractory diffuse large B-cell lymphoma patients","volume":"19","author":"Bachanova","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025100314192681000_9.4.e002056.31","doi-asserted-by":"crossref","unstructured":"Abramson JS , Gordon LI , Palomba ML , et al . Updated safety and long-term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in r\/r aggressive NHL. HemaSphere 2018;2. Abstract S800.","DOI":"10.1200\/JCO.2018.36.15_suppl.7505"},{"key":"2025100314192681000_9.4.e002056.32","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127566","article-title":"Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed\/refractory (r\/r) B cell non-Hodgkin lymphoma (NHL), including second-line transplant ineligible patients: Transcend NHL 001, Outreach, and PILOT","volume":"134","author":"Bachier","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100314192681000_9.4.e002056.34","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115252","article-title":"Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: an updated analysis of Juliet, a global pivotal phase 2 trial of tisagenlecleucel","volume":"132","author":"Schuster","year":"2018","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.8037","article-title":"Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"38","author":"Bachier","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"2025100314192681000_9.4.e002056.36","article-title":"Hospitalization patterns with commercial CAR T-cell therapy: a single institution experience","volume":"134","author":"Nasta","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.37","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125102","article-title":"CD20 targeted CAR-T for high-risk B-cell non-Hodgkin lymphomas","volume":"134","author":"Shadman","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hon.20_2629","article-title":"Baseline total metabolic tumour volume is highly prognostic for refractoriness to immunochemotherapy in DLBCL: an analysis of the phase 3 GOYA trial","volume":"37","author":"Trn\u011bn\u00fd","year":"2019","journal-title":"Hematol Oncol"},{"key":"2025100314192681000_9.4.e002056.39","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117199","article-title":"Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.40","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2018.36.15_suppl.3039","article-title":"Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma","volume":"36","author":"Locke","year":"2018","journal-title":"JCO"},{"key":"2025100314192681000_9.4.e002056.41","doi-asserted-by":"crossref","DOI":"10.1002\/hon.117_2630","article-title":"Cytokine release syndrome and neurotoxicity by baseline tumor burden in adults with relapsed or refractory diffuse large B-cell lymphoma treated with tisagenlecleucel","volume":"37","author":"Maziarz","year":"2019","journal-title":"Hematol Oncol"},{"key":"2025100314192681000_9.4.e002056.42","article-title":"Patient characteristics and pre-infusion biomarkers of inflammation correlate with clinical outcomes after treatment with the defined composition, CD19-targeted CAR T cell product, JCAR017","volume":"130","author":"Siddiqi","year":"2017","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.43","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125769","article-title":"Clinical and radiological correlates of neurotoxicity after standard of care axicabtagene ciloleucel in patients with relapsed\/refractory large B-cell lymphoma","volume":"134","author":"Strati","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.44","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129097","article-title":"Experience with Axicabtagene Ciloleucel (Axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T Consortium","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001694"},{"key":"2025100314192681000_9.4.e002056.46","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124364","article-title":"Medicare patients receiving chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma: a first real-world look at patient characteristics, healthcare utilization and costs","volume":"134","author":"Kilgore","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.47","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124694","article-title":"Comorbidities predict inferior survival in patients receiving CAR T-cell therapy for relapsed\/refractory DLBCL: a multicenter retrospective analysis","volume":"134","author":"Kittai","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.48","unstructured":"Memorial Sloan Kettering Cancer Center . CAR T Cell Therapy: A Guide for Adult Patients & Caregivers. New York, NY, 2020."},{"key":"2025100314192681000_9.4.e002056.49","doi-asserted-by":"crossref","unstructured":"Boyle N , McCord K . Social Work: Evaluation and Support. In: Maziarz RT , Slater SS , eds. Blood and Marrow Transplant Handbook. Springer, 2015: 55\u201365.","DOI":"10.1007\/978-3-319-13832-9_5"},{"key":"2025100314192681000_9.4.e002056.50","first-page":"20","article-title":"Building a program: implications for infrastructure, nursing education, and training for CAR T-cell therapy","volume":"23","author":"Taylor","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"2025100314192681000_9.4.e002056.51","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bbmt.2020.04.008","article-title":"Chimeric antigen receptor T cell therapy during the COVID-19 pandemic","volume":"26","author":"Bachanova","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100314192681000_9.4.e002056.52","unstructured":"Borchmann P , Tam CS , J\u00e4ger U , et al . An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). European Hematology Association, June 16, 2018; Stockholm, Sweden. Abstract #S799."},{"key":"2025100314192681000_9.4.e002056.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"2025100314192681000_9.4.e002056.54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"},{"key":"2025100314192681000_9.4.e002056.56","unstructured":"Institute for Clinical and Economic Review . Institute for Clinical and Economic Review: chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value\u2014Final evidence report 2018."},{"key":"2025100314192681000_9.4.e002056.57","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jnci\/djy193","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"111","author":"Sarkar","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2025100314192681000_9.4.e002056.58","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1200\/JCO.19.01691","article-title":"Innovation and access at the mercy of payment policy: the future of chimeric antigen receptor therapies","volume":"38","author":"Manz","year":"2020","journal-title":"JCO"},{"key":"2025100314192681000_9.4.e002056.59","unstructured":"Shah J . Achieving sustainable market and patient access: Medicare and Medicaid coverage, reimbursement, and coding issues for CAR-T. American Society of Gene & Cell Therapy Annual Meeting 2019."},{"key":"2025100314192681000_9.4.e002056.60","unstructured":"Centers for Medicare and Medicaid Services . Your Medicare benefits. Department of Health and Human Services, 2020."},{"key":"2025100314192681000_9.4.e002056.61","unstructured":"Centers for Medicare and Medicaid Services . Fiscal year (FY) 2020 inpatient prospective payment system (IPPS) and long term care hospital (LTCH) PPS changes. Department of Health and Human Services, 2019."},{"key":"2025100314192681000_9.4.e002056.62","unstructured":"Centers for Medicare and Medicaid Services . FY 2021 IPPS proposed rule home page. Available: https:\/\/www.cms.gov\/index.php\/medicare\/acute-inpatient-pps\/fy-2021-ipps-proposed-rule-home-page [Accessed 9 Sep 2020]."},{"key":"2025100314192681000_9.4.e002056.63","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129070","article-title":"Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital\u2019s perspective","volume":"134","author":"Yang","year":"2019","journal-title":"Blood"},{"key":"2025100314192681000_9.4.e002056.64","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-129215","article-title":"Estimation of total costs in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia receiving tisagenlecleucel from a US hospital\u2019s perspective","volume":"134","author":"Yang","year":"2019","journal-title":"Blood"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-002056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:19:38Z","timestamp":1759526378000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-002056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":64,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,12]]},"published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1136\/jitc-2020-002056"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-002056","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}